newsfilter
← Latest News
Business Wire·

Deciphera Pharmaceuticals Announces Planned 2024 Corporate Milestones Supporting Evolution to a Self-Sustaining, Multi-Product Company

– Preliminary Unaudited Fourth Quarter 2023 QINLOCK® Net Product Revenue of Approximately $46.0 Million, an Increase of 40% Compared to the Fourth Quarter of 2022 – – Expects to Submit Vimseltinib New Drug